Trial Profile
REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs VGX 3100 (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Registrational; Therapeutic Use
- Acronyms REVEAL 2
- Sponsors Inovio Pharmaceuticals
- 21 Sep 2023 Primary endpoint has been met (Percentage of Baseline biomarker-selected population) , according to an Inovio Pharmaceuticals media release.
- 09 Aug 2023 According to a Inovio Pharmaceuticals media release, based on biomarker data from this study, the company has decided to cease all further development of VGX-3100 as a potential treatment for cervical HSIL in the United States substantial work would be needed to refine this novel biomarker before it could be used in any further Phase 3 trials.
- 10 May 2023 According to a Inovio Pharmaceuticals media release, analysis of clinical characteristics of biomarker population is ongoing and findings to be shared in third quarter 2023